Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kunal Ramesh Chandekar
Observed names:
Kunal Chandekar,
Kunal R Chandekar,
Kunal R. Chandekar
Institution:
All India Institute of Medical Sciences
Observed institutions:
Post Graduate Institute of Medical Education and Research,
All India Institute of Medical Sciences
ORCID:
0009-0007-3599-0322
Observed ORCID:
0009-0007-3599-0322
OpenAlex ID:
A5064547859
FAPI PET/CT Imaging—An Updated Review
2023
·
Kunal Ramesh Chandekar
, Arun Prashanth
, et al.
·
Diagnostics
·
169
PDF
Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers
2023
·
Sanjana Ballal
, Madhav P. Yadav
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
35
PDF
Comparison of 18F-PSMA-1007 PET/CT With 68Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer
2022
·
Kunal Ramesh Chandekar
, Harmandeep Singh
, et al.
·
Clinical Nuclear Medicine
·
29
Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [ 177 Lu]Lu-DOTAGA.FAPi Dimer Therapy
2025
·
Sanjana Ballal
, Madhav Prasad Yadav
, et al.
·
Thyroid
·
26
177Lu-DOTATATE Plus Capecitabine Versus177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
2025
·
Swayamjeet Satapathy
, Piyush Aggarwal
, et al.
·
Journal of Nuclear Medicine
·
23
PDF
Impact of radioiodine therapy on recurrence and survival outcomes in intermediate‐risk papillary thyroid carcinoma —A systematic review and meta‐analysis
2023
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Clinical Endocrinology
·
20
PDF
Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy.
2021
·
Ashwin Singh Parihar
, Kunal Ramesh Chandekar
, et al.
·
Europe PMC (PubMed Central)
·
18
Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors
2025
·
Kunal Ramesh Chandekar
, Chandrasekhar Bal
·
Seminars in Nuclear Medicine
·
16
Head-to-Head Comparison Between [68Ga]Ga-DOTA.SA.FAPi And [18F]F-FDG PET/CT Imaging in Patients With Sarcoma
2025
·
Mohammad Sakir
, Sanjana Ballal
, et al.
·
Clinical Nuclear Medicine
·
14
Radioiodine versus no radioiodine outcomes in low‐risk differentiated thyroid cancers: A propensity‐score matched analysis
2023
·
Swayamjeet Satapathy
, Avinash Tupalli
, et al.
·
Clinical Endocrinology
·
11
PDF
Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial
2025
·
Swayamjeet Satapathy
, Piyush Aggarwal
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
8
[68 Ga]Ga-PSMA-11 Small Bowel Uptake in Crohn’s Disease: Revisiting the “Non-specificity” of PSMA Ligands
2022
·
Kunal Ramesh Chandekar
, Sindhu Tanigassalam
, et al.
·
Nuclear Medicine and Molecular Imaging
·
8
Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma
2025
·
Sanjana Ballal
, Mohammad Sakir
, et al.
·
Journal of Nuclear Medicine
·
7
Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer—a prospective exploratory study
2025
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Breast Cancer Research and Treatment
·
7
Low‐Dose Versus High‐Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer—A Real‐World Safety and Efficacy Analysis
2025
·
Jeepalem Sai Moulika
, Kunal Ramesh Chandekar
, et al.
·
Clinical Endocrinology
·
7
Utility of PSMA-PET derived volumetric parameters in initial risk stratification and prediction of prostate cancer metastasis – a head-to-head comparison of the radiotracers 18F-PSMA-1007 and 68Ga-PSMA-11
2024
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Nuclear Medicine Communications
·
5
Positron Emission Tomography/Computed Tomography in Thyroid Cancer
2024
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
PET Clinics
·
5
Clinical Outcomes of 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
2025
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Journal of Nuclear Medicine
·
4
Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment
2023
·
Swayamjeet Satapathy
, Kunal Ramesh Chandekar
, et al.
·
PET Clinics
·
4
Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN)
2025
·
Piyush Aggarwal
, Swayamjeet Satapathy
, et al.
·
Seminars in Nuclear Medicine
·
3
Utility of Novel Radiohybrid PSMA Ligands in PET Imaging of Biochemical Recurrence of Prostate Cancer—A Systematic Review and Meta-analysis
2025
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Clinical Nuclear Medicine
·
3
Plasma cell-free DNA as predictor of disease status in patients with differentiated thyroid cancer - a prospective study from a tertiary care institution
2024
·
Rashi Goel
, Swayamjeet Satapathy
, et al.
·
Frontiers in Oncology
·
3
PDF
Utility of18F-FDG PET/CT in Assessment of Disease Extent and Response to Treatment in Xanthoma Disseminatum
2023
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Journal of Nuclear Medicine Technology
·
3
PDF
Perirenal Fascia — an Uncommon Site of Metastases in Prostate Cancer Detected on 68Ga-PSMA-11 PET/CT
2023
·
Kunal Ramesh Chandekar
, Swayamjeet Satapathy
, et al.
·
Nuclear Medicine and Molecular Imaging
·
3
PDF
68Ga-PSMA-11 uptake in tracheal mucus plug – a potential pitfall
2022
·
Kunal Ramesh Chandekar
, Apurva Sood
, et al.
·
Nuclear Medicine and Molecular Imaging
·
3
Show more works
View as search
Works count:
36
Citation count:
438
H-index:
10
I10-index:
10
Year
Topic
Type